Clinical Trial Update: A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Describe a Phase II/III trial evaluating HLX07 plus serplulimab and chemotherapy versus a control combination of serplulimab or pembrolizumab with chemotherapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Non-small Cell Lung Cancer

Drugs mentioned

• HLX07 (HLX07)
• Pembrolizumab (pembrolizumab)
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Squamous NSCLC | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING